Introduction to Localized Scleroderma Management

Localized scleroderma (LSc), or morphea, is an autoimmune inflammatory disorder that primarily affects the skin, causing localized cutaneous sclerosis. While topical glucocorticoids remain a standard first-line approach, many patients experience insufficient clinical improvement. Recent advancements have identified phototherapy as a vital alternative. Specifically, using the excimer laser for morphea has emerged as an effective, minimally invasive strategy for managing plaques that do not involve extracutaneous tissues. However, understanding the exact molecular and histological shifts during this therapy is crucial for clinical optimization.

A recent case study of a 78-year-old woman highlights the potential of this modality. The patient presented with progressive, indurated plaques on her abdomen. Initial histopathology confirmed circumscribed morphea, showing dense collagen deposition alongside perivascular infiltration of lymphocytes and mast cells. After topical steroids failed, clinicians initiated 308-nm excimer laser therapy (ELT). The patient received 12 sessions over one year, with doses increasing from 100 mJ/cm² to 240 mJ/cm², totaling a cumulative dose of 2100 mJ/cm².

The Mechanism of Excimer Laser for Morphea

Research suggests that the efficacy of the excimer laser for morphea stems from its ability to modulate both immune and mesenchymal cell interactions. Histological analysis following the 12-session regimen revealed a near-complete resolution of dermal sclerosis. Furthermore, the therapy significantly reduced the infiltration of CD3+ T cells and mast cells. Most notably, ELT restored CD34 expression in dermal mesenchymal cells, which was entirely absent before treatment. Consequently, there was a marked reduction in α-smooth muscle actin-positive myofibroblasts, the primary drivers of fibrosis.

Moreover, the 308-nm wavelength is particularly efficient at inducing DNA breakage in lymphocytes, which triggers apoptosis and dampens the local inflammatory response. This dual action—reducing inflammation and reversing fibrotic cellular changes—makes ELT a superior choice for localized lesions. Clinicians should consider this therapy for patients with superficial inflammatory morphea who are refractory to conventional topical treatments.

Clinical Outcomes and Recommendations

The patient achieved significant clinical softening of the plaques and improved skin texture within twelve months. This case underscores that ELT does more than just alleviate symptoms; it fundamentally alters the fibrotic environment. Therefore, integrating ELT into the dermatological toolkit for morphea can provide better outcomes with fewer systemic side effects than long-term immunosuppressants. Practitioners should monitor patients for common side effects like transient hyperpigmentation or erythema while titrating the dose based on clinical response.

Frequently Asked Questions

How many sessions are typically required for ELT in morphea?

While individual responses vary, significant clinical improvement is often observed within 8 to 12 sessions administered every two to four weeks. Some cases may require longer durations to achieve complete resolution of sclerosis.

Is excimer laser therapy safe for elderly patients?

Yes, ELT is considered highly safe for elderly patients because it is minimally invasive and lacks the systemic toxicity associated with long-term corticosteroids or methotrexate.

Does excimer laser therapy work on deep morphea?

ELT is most effective for circumscribed or superficial morphea. Deep or generalized forms usually require systemic immunosuppressive therapy, though ELT may serve as an adjunct for specific superficial plaques.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Takahashi T et al. Circumscribed Morphea Successfully Treated With Excimer Laser: Analysis of Histopathological Changes. J Dermatol. 2026 Mar 18. doi: 10.1111/1346-8138.70225. PMID: 41847891.

2. Nisticò SP, et al. Phototherapy in localized scleroderma: A review. J Clin Med. 2023;12(10):3456.

3. Kreuter A, et al. German guidelines for the diagnosis and treatment of localized scleroderma. J Dtsch Dermatol Ges. 2016;14(2):199-216.